We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Home Office Circular 006/2013 covers a change to the Misuse of Drugs Regulations 2001 and the Misuse of Drugs (Designation) Order 2001.
The MHRA has issued an alert to heathcare professionals, as GlaxoSmithKline is recalling all unexpired stock of four types of Zantac, the medicine used to treat conditions such as heartburn and stomach ulcers.
The CMA has provisionally found that 4 pharmaceutical companies broke competition law in relation to the supply of an anti-depressant drug.
A letter was sent regarding InductOs (solvent and matrix for implantation) to inform of a potential shortage.
Man sentenced for unlawful importation and distribution of medicinal products.
European Medicines Agency has recommends the use of modafinil should be restricted to treat only sleepiness associated with narcolepsy - should no longer be used for obstructive sleep apnoea or chronic shift work sleep disorder.
The Medicines and Healthcare products Regulatory Agency (MHRA) are working closely with law enforcement agencies in India to prevent unlicensed medicines entering the UK.
Evidence indicates risks outweigh benefits.
Medicines have been taken out of the regulated medicines’ supply chain during distribution. The products have been parallel imported into the UK by Kosei Pharma, CST Pharma and Ordinant Medical Solutions from Italy and they have been re-labelled in Kosei...
A Change to the Misuse of Drugs Act 1971: control of synthetic cannabinoids and related compounds.
This circular draws attention to the contents of the below Statutory Instruments (SIs), S.I. 2018/1356 and 2018/1383, which will come into force at 00.01 on 1 April 2019.
Online learning module on reducing the side effects of steroid medicines to help clinicians to optimise the use of corticosteroids.
Company that sold vitamin and healthcare supplements to the vulnerable using high pressure sales tactics has been wound up in the courts.
Use has been restricted to 48 hours’ maximum parenteral use under specialist supervision, after a European safety review.
The CMA today alleged that Concordia and Actavis signed illegal agreements which enabled high prices for a life-saving drug to be prolonged.
Clinical trials have reported an increased risk of renal dysfunction and mortality in critically ill or septic patients who received hydroxyethyl starch (HES) compared with crystalloids.
ACMD Anabolic Steroids Advice (2011).
Most herbal medicines on the UK market are currently unlicensed products and it is difficult for consumers or healthcare professionals to identify which products are manufactured to acceptable standards with reliable product information.
There is a risk of rhabdomyolysis if Systemic fusidic acid (Fucidin) is given with statins.
Many food supplements contain hidden pharmaceutical ingredients that could be causing serious health risks, according to research
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).